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Colon cancer is a malignant neoplasm with high incidence and causes the death of more than 30% of the patients. 
Although there have been efforts to increase the life of the patient using chemotherapy agents, unspecified targets 
of drugs cause serious side effects and lead to multiple drug resistance (MDR). This is a major problem in cancer 
therapy in general. Efforts to use substances from plants that have low toxicity give new hope as a co-chemotherapy 
agent that can increase the efficacy of chemotherapy agents and reduce their toxicity to normal cells. This study 
aimed to determine the synergistic effects of therapy combination of Calotropis gigantea (EDCG) leaf extract with 
the chemotherapy drug 5-Fluorouracil (5-FU) and doxorubicin against WiDR colon cancer cells. The analysis results 
of MTT showed that the combination of EDCG and 5-Fluorouracil gives synergism effect at the dose combination of 
EDCG+5FU (3 µg/ml + 62.5 nM; 3 µg/ml + 125 nM; 3 µg/ml + 250 nM). While the combination of doxorubicin and 
EDCG creates antagonistic effects of mild to the strong antagonist, EDCG may enhance the efficacy of 5 Fluorouracil 







Colon cancer is included as five leading causes of death 
in the world other than breast, lung, stomach and liver cancer. 
Colon cancer causes 693,900 deaths per year (American Cancer 
Society, 2015). In developed countries like America, it has been 
reported in 2013 that there were new cases of 102,480 thousand 
colon cancers and 40,340 rectal cancers. These cause 50.830 
million deaths (NCI, 2013). Some attempts for colon cancer 
treatment have been done intensively like surgery, chemotherapy, 
and radiotherapy. Until now, cancer prevention efforts, mainly 
through chemotherapy, are still a failure. This is caused by the fact 
that chemotherapy drugs are not selective and specific in killing 
cancer cells causing serious side effects in patients. Cancer cell 
resistance to chemotherapy drugs is also the second cause of cancer 
treatment failure, so it is necessary to increase the therapeutic dose 
to keep giving anticancer activity (Tacar et al., 2013).
In general, almost all cancer chemotherapy drugs are 
a combination of several drugs. It is hoped that a combination 
of several chemotherapeutic agents may provide a synergistic 
effect and suppress the growth of cancer cells but with a toxicity 
profile that can still be tolerated. The use of such combinations is 
more clinically effective than single agents. However, until now, 
there has been no effective combination of cancer chemotherapy, 
especially when it comes to the metastasis phase. The use of 
cytotoxic agents for the treatment of this disease is confronted with 
the problem of cancer cell’s resistance to the drug. Chemotherapy 
agents often give high toxicity to normal organs (Putri et al., 2016). 
Hence, the development of therapies for cancer is very necessary. 
One approach that can be done is co-chemotherapy approaches 
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which combine a chemopreventive agent from natural materials 
with a chemotherapeutic agent, thereby increasing efficacy and 
decreasing the toxicity of chemotherapy on the normal tissue 
(Laksmiani et al., 2015; Putri et al., 2016).
Calotropis gigantea (C. gigantea) is a plant that has been 
investigated as potential anticancer properties. As reported by the 
researchers in a previous study, C. gigantea leaf ethanol extract can 
inhibit the growth of in vivo fibrosarcoma at doses of 100 and 150 
mg/kg with the mechanism of increased expression of caspase-3 
(Mutiah et al., 2016). Ethanol extract of the roots and C. gigantea 
leaves have an anticancer activity which is higher than the flower 
(Mutiah et al., 2016). Ethyl acetate fraction from the leaves (IC50 41, 
79 µg/mL) and dichloromethane fraction (IC50 40.57 μg/mL) have 
cytotoxic activity which is higher than butanol fraction (IC50 737.74 
ug/mL) and water (IC50 8493 ug/mL) (Mutiah et al., 2017). This 
study tested the effectiveness of a combination of C. gigantea leaf 
extract with 5 fluorouracil and doxorubicin drug chemotherapy on 
WiDrcolon cancer cells. The use of such combinations is expected 
to produce synergistic effects of both. The effect is much larger than 
the cumulative effect of the use of the single effect. Meanwhile, the 
toxic effects caused can be minimized since the concentration used 
is also relatively low, below the IC50 (Putri et al., 2016).
MATERIAL AND METHODS
Test material
The plant materials used in this study are the leaves of 
C. gigantea taken from Malang, East Java.  Plant determination 
was done at Indonesian Institute of Sciences (LIPI) in Purwodadi, 
East Java. The plant specimens were stored in the laboratory of 
Pharmacognosy at UIN Maulana Malik Ibrahim Malang No. 
16030232.
Materials for extraction
The solvent used for the extraction step maceration is 
70% ethanol (Merck).
Cell culture material
Cancer cell used in this study is a WiDr colon cancer 
cell line. Cells were obtained from the Cancer Chemoprevention 
Research Center (CCRC), Faculty of Pharmacy in Gadjah Mada 
University and Prof. Masasi Kawaichi, Laboratory of Gene 
Function in Animal, Graduate School of Biological Sciences, 
Nara Institute of Science and Technology. Cells were cultured 
in Rosewell Park Memorial Institute (RPMI) in medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(PAA Laboratories), 1% v/v penicillin-Streptomycin (Nacalay 
Tesque), and 1.0 mM L-glutamine (Nacalai Tesque). Then the 
cells were incubated in an incubator with 5% CO2 and 95% O2 at 
37oC.
Cytotoxic test material
Dimethyl sulfoxide (DMSO) was used to dissolve the 
extract of C. gigantea (EDCG) leaf. The concentration used in 
this study was a maximum of 1% in the culture medium. 0.025% 
trypsin was used to harvest cells. Phosphate buffer saline (PBS) 
was used as a wash buffer solution. 3-(4,5-dimetiltiazole-2-yl)-2,5-
diphenyltetrazolium (MTT) was used as a reagent that reacts with 
the succinate dehydrogenase enzyme in the cell. 5 Fluorouracil, 
Doxorubicin was used as chemotherapy agents combined with 
EDCG.
Tools
The main tools needed in this research are macerator, 
evaporator, centrifugation, liquid nitrogen tank, CO2 - Jacketed 
Incubator, contrast phase microscopy, Laminar Air Flow cabinet 
(Nuaire), and Elisa reader.
Extraction
A total of 500 mg of C. gigantea leaf powder was 
macerated using 3 liters of 70% ethanol for 48 hours. Then, it was 
filtered and the filtrated before being separated. The residue was 
then dried and re-macerated with 3 liters of 70% ethanol for 48 
hours. This process was repeated for four times. After that, the 
filtrate was collected and evaporated in a vacuum rotary evaporator 
to obtain a thick extract. The condensed extract was then dried in 
an oven at 40°C. (BPOM, 2010).
Anticancer combination test with MTT method
100 µl of WiDr colon cancer cell suspension at a density 
of 3 × 104 cells/100 µl media was distributed into wells in 96-well 
plate and incubated for 24 hours. After incubation, 100 µl of test 
solution at different concentrations was added to wells. The test 
solution used was EDCG with a combination of 5 fluorouracil and 
doxorubicin. As a positive control, 100 μl of culture medium, then 
100 μl of doxorubicin and 5 fluorouracil at various concentrations 
were added into wells containing 100 μl of WiDr cancer cells. As 
a cell control, 100 μl of culture medium was added to the well 
containing 100 μl of cell suspension and as a solvent control. 
100 μl of DMSO was added to the well containing 100 μl of 
culture medium and 100 μl of cell suspension with dilutions 
corresponding to the dilutions of test solution concentration, 
then it was incubated for 24 hours in an incubator with a flow 
of 5% CO2 and 95% O2. At the end of the incubation, the culture 
medium was discarded and then 10 μl solution of MTT (5 mg/
μlPBS) was added, and the medium was replaced with 190 μl of 
complete 1640 RPMI medium. Then, cells were incubated for 3-4 
hours. MTT reaction was stopped by adding SDS stopper reagent 
(100 μl). The microplate was then wrapped with tissue paper and 
incubated for overnight at room temperature in dark. Living cells 
react with MTT forming purple color. The test result is read by 
ELISA reader at a wavelength of 595 nm (Mutiah, 2014).
Data analysis
The data obtained are in the form of absorbance of each 
well converted to a percentage of living cells:
Description: Abs: absorbance
The percentage of living cells is calculated to obtain 
the IC50 value, which is the concentration that causes growth 
inhibition of 50% of cells population where the cytotoxic potential 
can be known. IC50 values were determined by probit analysis 
(Statistical Product and Service Solution (SPSS) 16.0 for 
Windows). Combined cytotoxicity was determined by calculating 
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the interaction index between chemotherapy agents with EDCG, 
using the equation:
Combination Index/CI = (D) 1/(Dx) 1 + (D) 2/(Dx) 2
Where D1 and D2 are the sample concentrations used 
in the combination treatment. (Dx) 1 and (Dx) 2 are single 
concentration which can produce the effect of a given treatment 
combination (Reynolds and Maurer, 2005). CI or Combination 
Index gained is interpreted as follows: < 0.1 means the synergy is 
very strong, 0.1−0.3 is a very strong synergy, 0.3−0.7 is synergist, 
0.7−0.9 is mild-moderate synergy, 0.9−1.1 is the mild-moderate 
antagonist, 1.45−3.3 is the antagonist, 3.3 > strong-powerful 
antagonist.
Fig. 1: Comparison of cell growth inhibitory effects (anticancer activity) for the treatment of test material on WiDrcolon cancer cells with MTT reduction method.
RESULT AND DISCUSSION
Results
Analysis of combination results of EDCG+5-fluorouracil (5 FU) and 
EDCG+Doxorubicin (DOX) on morphology and viability of cells
The concentration used in the test is a combination 
of 16 combination doses with a concentration below IC50. The 
percentage of viable cells was determined using the MTT method. 
The result of the effectiveness of combination forms is compared 
with the single therapy, so they can compare the efficacy of the 
combination preparation on the single stocks.
In EDCG treatment, 5-FU and DOX either singly or in 
combination lead to morphological changes in WiDrcells which 
were linear with the increasing concentrations of the test. WiDr 
cells in the control look oval with clear cytosol and attached to the 
basic Tissue Culture Dish (TCD). After the test material treatment, 
some cells appear rounded and detached from TCD. The cell looks 
dull and compact, it looks like it is condensed and undergoes core 
and granulation shrinkage in the cytosol. The morphological 
changes are more pronounced along with the increase in test 
concentration. In line with the morphological changes, single 
and combination material test decrease the viability of the WiDr 
cells which are linear with the increasing concentration of the test. 
In the control treatment, there is no change in cell morphology, 
in which the cells’ shape is oval, looks like clear cytosol and is 
attached to the basic TCD (Figure 1).
104 cells per well were put in 96 well plates, incubated 
for 24 hours in complete RPMI media, which were then treated 
with single and combination test preparation. Cell morphology 
was observed under a contrast phase microscope using 200x 
magnification. A) Control of WiDrcolon cancer cell DMSO 
treatment; B) C. gigantea Leaf Extract monotherapy (EDCG) 
Treatment; C) Treatment of Doxorubicin monotherapy; D) 
5-Fluorouracil monotherapy treatment; E) Treatment of 
combinations of EDCG and doxorubicin; F) Treatment of 
EDCG and 5-Fluorouracil combination. The changes that 
occurred can be seen at test material treatments indicated by 
the cells that undergo cell death as the cells are detached from 
TCD and blebbing happened (b, c), are dull (e); are enlarged 
(d, f). The living cell is shown by the arrow (a). The experiment 
is performed with 3× replications.
The treatment of EDCG+5-FU combination for WiDr 
colon cancer cell causes deeper cell viability decrease compare to 
the treatment of EDCG+DOX combination. The increase of EDCG 
dose for the combination with 5 FU causes the decrease of WiDr 
colon cancer cell viability. The graphic picture of isobologram is 
presented below (Figure 2):
A) The treatment of EDCG+5-fluorouracil (5-FU) 
therapy combination gives synergist effect.
B) The treatment of EDCG+doxorubicin (DOX) therapy 
combination gives antagonist effect.
104 cells/same age is plated in the well plate, incubated 
for 24 hours in the RPMI media with or without EDCG+5-FU 
combination treatment and EDCG+DOX combination with 
determined concentration. Cell viability is determined by MTT 
method. The analysis result is a representation from two different 
experiments; each of them is done with three replications.
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Fig. 2: The influence of treatment of EDCG+5-FU combination and EDCG+DOX combination for the growth of WiDr colon cancer cell.
The analysis of index combination result
The methods used in the evaluation of EDCG+5-FU 
and EDCG+DOX combinations are Isobologram and Index 
Combination (IC). IC analysis produces a score of the quantitative 
parameter that describes the efficacy of combination by using 
the equation of IC = (D) 1/(Dx) 1 + (D) 2/(Dx) 2. IC is used to 
determine additive effect from two compound combinations, 
whether in form of synergist, additive, or antagonist effects.
The result of EDCG+5-FU Index Combination analysis 
shows that from 16 combination doses, there are three doses 
combinations that give synergist effect, they are EDCG+5-FU 
(3 µg/ml + 62.5 nM; 3 µg/ml + 125 nM; 3 µg/ml + 250 nM). 
Other doses give light synergist, antagonist, strong antagonist, and 
powerful antagonist effects. The EDCG+5-FU Index Combination 
analysis result is presented in Table 1 and Figure 3A. The result 
of EDCG+DOX Index Combination analysis shows that from 16 
combination doses, the combination which shows no synergism 
effect but that combination gives light antagonist up to powerful 
antagonist effect. The table of the analysis result of EDCG+DOX 
Index Combination is presented in Table 2 and Figure 3B.
A) EDCG+5 FU combination treatment for WiDr colon 
cancer cell gives synergist up to strong antagonist effects. B) 
EDCG+DOX combination treatment for WiDr colon cancer cell 
gives antagonist up to strong antagonist effect. The combination 
test is done with each four concentration series under IC5 
concentration Index Combination, < 0.1 powerful synergist, 
0.1−0.3 strong synergist, 0.3−0.7 synergist, 0.7−0.9 light-medium 
synergist, 0.9−1.1 light-medium antagonist, 1.45−3.3 antagonist, 
3.3 > strong-powerful antagonist.
Discussion
The objective of this research is to know the efficacy of C. 
gigantea (EDCG) leaf extract in combination with 5-Fluorouracil 
(5 FU) and doxorubicin (DOX) as chemotherapy medicines. The 
cancer cells used in this test was WiDr colon cancer cells. WiDr 
cell is human colon cancer cell that was successfully isolated 
from a 78 years old female patient. These cells were successfully 
derived from HT-29 cells (Nurulita et al., 2011). The specifications 
of WiDr cells are, able to produce carcinoembryonic antigen and 
can finish one cell cycle in 15 hours (Dai et al., 2012).
Table 1: The analysis result of Index Combination of EDCG+5-FU combination 
treatment for WiDr colon cancer cell.
Doses combination Cell viability(mean ± SD)* CI Therapy effects
EDCG (µg/ml) 5 FU (nM) means ± SD
3 31.25 57.08 ± 1.18 1.24 Antagonist
6 31.25 48.04 ± 0.33 22.06 Powerful Antagonist
9 31.25 35.39 ± 2.16 702.55 Powerful Antagonist
12 31.25 35.76 ± 1.03 857.49 Powerful Antagonist
3 62.5 68.90 ± 0.86 0.3 Synergist
6 62.5 56.25 ± 2.40 0.87 Light Synergist
9 62.5 37.69 ± 5.17 2.46 Antagonist
12 62.5 29.17 ± 4.26 4.39 Powerful Antagonist
3 125 60.06 ± 3.15 0.4 Synergist
6 125 59.59 ± 16.99 0.79 Antagonist
9 125 34.92 ± 2.54 2.7 Strong Antagonist
12 125 31.42 ± 2.09 4.07 Strong Antagonist
3 250 68.06 ± 3.09 0.35 Synergist
6 250 52.43 ± 2.79 1 Antagonist
9 250 33.30 ± 2.82 2.86 Antagonist
12 250 25.30 ± 3.64 5.02 Powerful Antagonist
*Means of cell viability test ± Deviation, n = 3.
Doxorubicin and Fluorouracil 5 are selected chemotherapy 
agents that have been used more than three recent decades. However, 
the use of those chemotherapy agents is still limited because of 
many side effects (Putri et al., 2016). The side effects caused by 
doxorubicin chemotherapy are immunosuppression, nauseous, 
and reversible arrhythmia. Long-term use of doxorubicin causes 
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cardiomyopathy effect followed by heart failure. The side effect 
caused by doxorubicin depends on used doses. Therapy strategy in 
the form of combination with a natural chemopreventive agent in 
the lower doses combination under IC50 can improve the efficacy of 
chemotherapy medicine and reduce the side effect.
Fig. 3: Index Combination in the EDCG+5FU and EDCG+DOX combination treatments.
Table 2: The analysis result of Index Combination of EDCG+DOX combination 
treatment for WiDr colon cancer cell.
Doses combination Cell viability(means ± SD)* IC Therapy effect
EDCG (µg/ml) Dox (nM) means ± SD
3 25 65.41 ± 2.99 1.03 Light antagonist
6 25 58.91 ± 0.57 1.18 Light antagonist
9 25 61.15 ± 1.19 1.67 Antagonist
12 25 61.53 ± 0.71 2.13 Antagonist
3 50 77.76 ± 10.16 15.5 Powerful Antagonist
6 50 63.77 ± 3.05 1.76 Antagonist
9 50 49.67 ± 0.38 2.18 Antagonist
12 50 57.54 ± 4.37 2.39 Antagonist
3 100 59.84 ± 3.18 1.32 Light Antagonist
6 100 60.27 ± 1.09 1.87 Antagonist
9 100 59.67 ± 4.12 2.28 Antagonist
12 100 62.35 ± 2.48 3.16 Antagonist
3 200 70.44 ± 4.28 14.5 Powerful Antagonist
6 200 65.74 ± 1.23 6.2 Powerful Antagonist
9 200 56.39 ± 3.36 2.5 Antagonist
12 200 50.33 ± 2.70 3.01 Antagonist
*Means of cell viability test ± Deviation, n = 3.
5 FU is one of the drugs of choice in the cancer therapy. 
The use of 5 FU is suggested in the form of combination with 
another chemotherapy agent. It is caused by the decrease of 5 FU’s 
sensitivity for a cancer cell. Several side effects caused by cancer 
therapy with 5 FU chemotherapy agent are stomatitis, neutropenia, 
diarrhea, and hand-foot syndrome (Hess et al., 2010). The use of 5 
FU for the long term may possibly cause cardiotoxicity, even though 
it is rare (Rodgers et al., 2010). The excessive of 5 FU, compared 
to other chemotherapy medicine, is having higher selectivity and 
lower side effect. Nevertheless, 5 FU’s selectivity for cancer cell 
is still reaching 15% so that until now the chemotherapy agent is 
still needed to be developed to improve the efficacy of 5 FU (Parhi 
et al., 2012).
In the analysis of Index Combination (IC) EDCG+5-FU, 
it is obtained synergism effect in the three doses combinations; 
they are 3 µg/ml + 62.5 nM, 3 µg/ml + 125 nM and 3 µg/ml +250 
nM. The synergism effect of EDCG+5-FU combinations is a 
greater effect compared to every effect summation in its sole form. 
The synergism effect of those combinations is caused by activity 
mechanism that supports each other among terpenoids compounds 
contents in the EDCG and 5 FU chemotherapy medicine. Similar 
results were reported by Alwi et al. (2017) where a combination of 
5FU-Leucovorin with Phaleria macrocarpa has greater synergist 
effect when compared to the individual effect on mouse strain of 
adenocarcinoma.
Leaf extract of Calotropis gigantea (EDCG) has been 
reported of its ability in impeding the growth of cancer cell through 
apoptosis induction by raising the three caspase expression 
(Mutiah, 2016). While the 5 Fluorouracil is a chemotherapy agent 
with a working mechanism through improving the expressions 
of p21 and pRb without involving the role of p53. Protein P21 
has a very important role in the checkpoint system of G1 phase. 
P21 expression causes the inhibition of cell cycle in the G1 and 
S phases caused by the E/CDK2 and A/CDK2 cycling activity 
inhibitions. The impeding of the cell cycle in the G1 and S 
phases causes cancer cell apoptosis induction (Meiyanto, 2011). 
The synergism effect of EDCG+5 FU combination is presumed 
that EDCG can be inducted and it can improve 5 FU efficacy 
through cancer cell apoptosis intrinsic path. For the synergism 
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effect of molecular mechanism, EDCG+5 FU must be proven 
further.
CONCLUSION
The combination of EDCG and 5-Fluorouracil gives 
synergism effect at the dose combination of EDCG+5FU (3 
µg/ml + 62.5 nM; 3 µg/ml + 125 nM; 3 µg/ml + 250 nM). The 
combination of doxorubicin and EDCG creates antagonistic 
effects of mild to the strong antagonist. EDCG may enhance the 
efficacy of 5 Fluorouracil but decrease the efficacy of doxorubicin. 
Therefore, a combination of EDCG and 5-Fluorouracil may be 
recommended for further study.
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